• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Opiant Pharmaceuticals, Inc. - Common Stock (NQ:OPNT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 20.80 (24)
Ask (Size) 24.99 (1)
Prev. Close 20.65
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 4,399,675
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio ↗
March 03, 2023
Indivior PLC (OTCPK:INVVY) (LSE:INDV) has completed the acquisition of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) The transaction strengthens Indivior's addiction treatment and science portfolio by... 
Via Benzinga
News headline image
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
February 07, 2023
From Opiant Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

More News

Read More
News headline image
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
February 06, 2023
From Opiant Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
January 19, 2023
From Opiant Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT
January 06, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Analyzing Opiant Pharma's Short Interest ↗
January 03, 2023
Via Benzinga
News headline image
How Is The Market Feeling About Opiant Pharma? ↗
December 08, 2022
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
December 05, 2022
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗
November 15, 2022
Via Benzinga
News headline image
Tesla, Amazon, Opiant, Nu, Paramount: Lawsuit, Earnings, Warren Buffett's Increased Stake Draw Investor Attention ↗
November 14, 2022
Via Benzinga
News headline image
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT
November 14, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Looking Into Opiant Pharma's Recent Short Interest ↗
November 14, 2022
Via Benzinga
News headline image
Dow Surges 150 Points; Crude Oil Falls Sharply ↗
November 14, 2022
Via Benzinga
News headline image
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗
November 14, 2022
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
November 14, 2022
Via Benzinga
News headline image
Opiant Pharmaceuticals (NASDAQ: OPNT) Enters Into Definitive Agreement to be Acquired by Indivior for $145 Million
November 14, 2022
Via Spotlight Growth
News headline image
Stocks Cool Off From Last Week's Rally ↗
November 14, 2022
Via Talk Markets
News headline image
Silver Rises Over 1%; Tyson Foods Posts Downbeat Earnings ↗
November 14, 2022
Via Benzinga
News headline image
Party City Layoffs 2022: What to Know About the PRTY Job Cuts ↗
November 14, 2022
Via InvestorPlace
News headline image
Why Is Opiant Pharma (OPNT) Stock Up 116% Today? ↗
November 14, 2022
Via InvestorPlace
News headline image
US Stocks Mostly Lower; Nasdaq Drops Over 100 Points ↗
November 14, 2022
Via Benzinga
News headline image
OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders
November 14, 2022
From Halper Sadeh LLC
Via Business Wire
News headline image
Facebook Stalls Portal & Smartwatch Projects, Visa Breaks Debit Card Tie Up With FTX, $3B Bitcoin Withdrawn From Crypto Exchanges: Top Stories Monday, Nov. 14 ↗
November 14, 2022
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
November 14, 2022
Via Benzinga
News headline image
Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals ↗
November 14, 2022
Via Benzinga

Frequently Asked Questions

Is Opiant Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Opiant Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Opiant Pharmaceuticals, Inc. - Common Stock trade on?
Opiant Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Opiant Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Opiant Pharmaceuticals, Inc. - Common Stock is OPNT on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap